Comment
doi: 10.1016/j.contraception.2021.03.012.
Epub 2021 Mar 16.
Author response to ethinyl estradiol and levonorgestrel Phase 3 data clarification
Affiliations
- PMID: 33741355
- DOI: 10.1016/j.contraception.2021.03.012
Item in Clipboard
Comment
Author response to ethinyl estradiol and levonorgestrel Phase 3 data clarification
Contraception.
2021 Aug.
No abstract available
Conflict of interest statement
Declaration of competing interest Grants/Research: Agile Pharmaceutical, Merck, Mithra, Sebela Pharmaceutical Honoraria/Speakers Bureau: American Regent, Bayer HealthCare, Merck, TherapeuticsMD Consultant/Advisory Board: Agile Pharmaceutical, AMAG, Bayer HealthCare, Merck, TherapeuticsMD.
Comment on
-
Efficacy, safety, and tolerability of a levonorgestrel/ethinyl estradiol transdermal delivery system: Phase 3 clinical trial results.Contraception. 2021 Mar;103(3):137-143. doi: 10.1016/j.contraception.2020.11.011. Epub 2020 Nov 28. Contraception. 2021. PMID: 33259782 Clinical Trial.
-
Ethinyl estradiol and levonorgestrel patch phase 3 data clarification.Contraception. 2021 Aug;104(2):216. doi: 10.1016/j.contraception.2020.12.017. Epub 2021 Mar 17. Contraception. 2021. PMID: 33744301 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
